Neurometabolite Changes After Transcranial Photobiomodulation in Major Depressive Disorder: A Randomized Controlled Trial Investigating Dose-Dependent Effects
Journal of Clinical Medicine · 13.05.2025 · 14 (10) · 3402
DOI: 10.3390/jcm14103402 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 13.05.2025. Verfasst von David R A Coelho und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuropsychiatry and Neuromodulation, Massachusetts General Hospital, Boston, MA 02129, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: US National Institute of Mental Health, Brain & Behavior Research Foundation.
Abstract (Originalsprache)
Background
Transcranial photobiomodulation (t-PBM) is a promising non-invasive therapy for Major Depressive Disorder (MDD). MDD is associated with altered brain metabolism, including changes in N-acetylaspartate (NAA), choline (Cho), and creatine (Cr). This study assessed the effects of varying t-PBM doses on neurometabolite levels in the dorsolateral prefrontal cortex (dlPFC) and their correlations with clinical outcomes.
Methods
In this randomized, sham-controlled, cross-over study, 33 adults with MDD received one session of t-PBM at low, medium, and high doses and a sham treatment. Proton magnetic resonance spectroscopy (1H-MRS) measured NAA, Cho, and Cr pre- and post-treatment. Clinical outcomes were assessed using the Montgomery–Åsberg Depression Rating Scale (MADRS) and the Symptoms of Depression Questionnaire (SDQ). Statistical analyses included paired t-tests or Wilcoxon signed-rank tests for neurometabolite changes, and linear mixed-effects regression models for t-PBM dose, neurometabolites, and time effects.
Results
NAA levels increased significantly (7.52 ± 0.777 to 8.12 ± 1.05 mmol/L for one session; 7.36 ± 0.85 to 7.85 ± 0.68 mmol/L across all sessions); however, these changes were not associated with specific t-PBM doses or sham. No significant changes were observed for Cho and Cr levels. Positive correlations were found between Cho levels and MADRS scores (r = 0.59, p = 0.017), and negative correlations between Cr levels and SDQ scores at the medium dose (r = −0.91, p = 0.011).
Conclusions
While NAA levels increased, and correlations between neurometabolites and clinical outcomes were observed, these findings do not suggest a specific effect of t-PBM. Larger randomized controlled trials with optimized dosing protocols, extended follow-up, and advanced spectroscopy are needed to clarify the neurometabolic therapeutic potential of t-PBM in MDD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Neuropsychiatry and Neuromodulation, Massachusetts General Hospital, Boston, MA 02129, USA.
- Department of Psychiatry, Harvard Medical School, Boston, MA 02114, USA.
- Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.
- Department of Psychiatry, New York University Grossman School of Medicine, New York, NY 10016, USA.
- Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA 02129, USA.
- Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.
ORCID-Profile: David R A Coelho, Ümit Tural, Katherine Anne Collins, Kari Siu, Paolo Cassano, Akila Weerasekera
Förderung
- US National Institute of Mental Health
- Brain & Behavior Research Foundation
Zitieren
APA
Coelho, D. R. A., Tural, Ü., Hurtado Puerto, A. M., Collins, K. A., Gersten, M. B., Parincu, Z., Siu, K., Iosifescu, D. V., Ratai, E. M., Cassano, P., & Weerasekera, A. (2025). Neurometabolite Changes After Transcranial Photobiomodulation in Major Depressive Disorder: A Randomized Controlled Trial Investigating Dose-Dependent Effects. Journal of Clinical Medicine, 14(10), 3402. https://doi.org/10.3390/jcm14103402
Vancouver
Coelho DRA, Tural Ü, Hurtado Puerto AM, Collins KA, Gersten MB, Parincu Z, et al. Neurometabolite Changes After Transcranial Photobiomodulation in Major Depressive Disorder: A Randomized Controlled Trial Investigating Dose-Dependent Effects. Journal of Clinical Medicine. 2025;14(10):3402. doi:10.3390/jcm14103402
BibTeX
@article{Coelho2025,
author = {Coelho, David R A and Tural, Ümit and Hurtado Puerto, Aura Maria and Collins, Katherine Anne and Gersten, Maia Beth and Parincu, Zamfira and Siu, Kari and Iosifescu, Dan Vlad and Ratai, Eva-Maria and Cassano, Paolo and Weerasekera, Akila},
title = {Neurometabolite Changes After Transcranial Photobiomodulation in Major Depressive Disorder: A Randomized Controlled Trial Investigating Dose-Dependent Effects},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {10},
pages = {3402},
doi = {10.3390/jcm14103402}
}
EUVIMED